Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of argenex SE (NASDAQ:ARGX)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of argenex SE (NASDAQ:ARGX). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in argenex stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

argenex Trading Up 0.4%

Shares of ARGX stock traded up $3.75 on Thursday, reaching $981.33. The company’s stock had a trading volume of 449,412 shares, compared to its average volume of 353,577. The stock’s fifty day simple moving average is $927.22 and its 200-day simple moving average is $859.56. argenex SE has a 1 year low of $661.85 and a 1 year high of $1,072.75. The company has a market capitalization of $61.72 billion, a price-to-earnings ratio of 34.24, a price-to-earnings-growth ratio of 0.90 and a beta of 0.48.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a net margin of 31.66% and a return on equity of 47.70%. The business had revenue of $1.75 billion during the quarter. Equities research analysts forecast that argenex SE will post 28.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ARGX shares. DZ Bank reissued a “buy” rating on shares of argenex in a research note on Friday, October 9th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 21st. HC Wainwright raised their price objective on argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Truist Financial lifted their target price on argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Oppenheimer dropped their target price on argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a report on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,158.76.

Hedge Funds Weigh In On argenex

Several institutional investors and hedge funds have recently bought and sold shares of the company. Eastern Bank purchased a new stake in shares of argenex during the second quarter worth about $32,000. Axiom Investment Management LLC purchased a new position in shares of argenex in the 1st quarter valued at approximately $50,000. Harbour Investments Inc. raised its position in shares of argenex by 966.7% in the 3rd quarter. Harbour Investments Inc. now owns 64 shares of the company’s stock valued at $62,000 after purchasing an additional 58 shares during the last quarter. Richardson Financial Services Inc. purchased a new position in shares of argenex in the 3rd quarter valued at approximately $66,000. Finally, Bogart Wealth LLC boosted its stake in argenex by 2,500.0% in the 3rd quarter. Bogart Wealth LLC now owns 78 shares of the company’s stock worth $75,000 after purchasing an additional 75 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.